Cite

HARVARD Citation

    Rummel, M. et al. (2021). A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study). British journal of haematology. pp. 1123-1133. [Online]. 
  
Back to record